Efavirenz + Daclatasvir = Precautionary

Effect on Concentration

Efavirenz
Decrease
Applies within class?
No
Daclatasvir
No change
Applies within class?
No

Pharmacologic Effects

Efavirenz
Effect
N/A
Applies within class?
No
Daclatasvir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 09-Jul-2018

Summary

The manufacturer recommends increasing the dose of DCV to 90mg QD when coadministered with efavirenz.

Sources

Efavirenz vs Daclatasvir ^

Study Design

*This interaction has not been formerly studied, but inferences are drawn from knowledge of the metabolic and transport pathways of each of the drugs.

Study Results

The manufacturer states that coadministration of daclatasvir with inhibitors or inducers of either CYP3A or P-gP may alter daclatasvir concentrations.

Study Conclusions

Inhibitors of P-gP or CYP3A may increase daclatasvir concentrations, while inducers of this enzyme and transport protein may decrease daclatasvir concentrations.

References

Garimella T, You X, Wang R, Huang SP, Kandoussi H, Biffano M, Eley T. A review of daclatasvir drug-drug interactions. Advances In Therapy. 2016; 11: 1867-1884.